Evidence map›Paper›PMID 34195486›Full record

ArticleAdvances in radiation oncology

Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors.

Sai Duriseti, James Kavanaugh, Sreekrishna Goddu, Alex Price, Nels Knutson, Francisco Reynoso, Jeff Michalski, Sasa Mutic, Clifford Robinson, Matthew B Spraker

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 64 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04133415 nacompletednot on this map

A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

TypeinterventionalSponsorWashington University School of MedicineRan2019 to 2020Enrolled20ConditionsCancer, Palliative RadiotherapyArmsLattice stereotactic body radiation therapy, Peripheral blood
NCT04553471 nacompletednot on this map

A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

TypeinterventionalSponsorWashington University School of MedicineRan2020 to 2023Enrolled70ConditionsSarcoma, Thoracic Cancer, Abdominal Cancer, Pelvic CancerArmsStereotactic body radiotherapy, Research blood draw
NCT07000162 phase2recruitingnot on this map

LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial (LART Trial)

TypeinterventionalSponsorAzienda USL Reggio Emilia - IRCCSRan2025 to 2028Enrolled56ConditionsCancer, Palliative RadiotherapyArmsLattice radiation therapy
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Feasibility, safety, and clinical outcomes analysis of dense-lattice radiation therapy in palliative care for cancer patients´.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sai DurisetiDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
James KavanaughDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Sreekrishna GodduDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Alex PriceDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Nels KnutsonDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Francisco ReynosoDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Jeff MichalskiDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Sasa MuticDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Clifford RobinsonDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Matthew B SprakerDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Washington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStereotactic body radiation therapy (SBRT) has demonstrated clinical benefits for patients with metastatic and/or unresectable cancer. Technical considerations of treatment delivery and nearby organs at risk can limit the use of SBRT in large tumors or those in unfavorable locations. Spatially fractionated radiation therapy (SFRT) may address this limitation because this technique can deliver high-dose radiation to discrete subvolume vertices inside a tumor target while restricting the remainder of the target to a safer lower dose. Indeed, SFRT, such as GRID, has been used to treat large tumors with reported dramatic tumor response and minimal side effects. Lattice is a modern approach to SFRT delivered with arc-based therapy, which may allow for safe, high-quality SBRT for large and/or deep tumors. METHODS AND MATERIALS: Herein, we report the results of a dosimetry and quality assurance feasibility study of Lattice SBRT in 11 patients with 12 tumor targets, each ≥10 cm in an axial dimension. Prior computed tomography simulation scans were used to generate volumetric modulated arc therapy Lattice SBRT plans that were then delivered on clinically available Linacs. Quality assurance testing included external portal imaging device and ion chamber analyses.

resultsAll generated plans met the standard SBRT dose constraints, such as those from the American Association of Physicists in Medicine Task Group 101. Additionally, we provide a step-by-step approach to generate and deliver Lattice SBRT plans using commercially available treatment technology.

conclusionsLattice SBRT is currently being tested in a prospective trial for patients with metastatic cancer who need palliation of large tumors (NCT04553471, NCT04133415).

Identifiers

PMID34195486
PMCPMC8233471
OpenAlexW3118866204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.